Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)
Clinical trial NCT03909165 · COMPLETED
Trial details
- NCT number
- NCT03909165
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2019-07-23
- Primary completion
- 2023-09-21
- Enrollment
- 145
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.